StockData
Illumina, Inc. logo

Illumina, Inc. (ILMN) KPIs and segments

ILMNNasdaqLaboratory Analytical InstrumentsFiscal year ends January 3
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 27, 2026Last filing: 10-Q on Oct 30, 2026Score 14/3013% above fair value
$210.01+7.40 (+3.65%)

Close on Nov 18, 2026Market cap $31.75BP/E 36.0Yield –

KPI & bộ phận

Chỉ số vận hành và bộ phận làm nên hoạt động của Illumina · năm tài chính kết thúc ngày 28 tháng 12

Nhìn nhanh KPI của Illumina: 36 chỉ số vận hành, trong đó có Remaining Performance Obligations, Total Contract Liabilities — Deferred Revenue và High-Throughput Sequencing Volume Share on NovaSeq X, lấy từ 158 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.

Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.

Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.

Thêm vào biểu đồChỉ số
Q3 2026
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
Core Illumina($M)
1,1291,1591,0911,1591,0841,0591,0411,1041,0801,0921,0561,097
Sequencing($M)3
1,0211,0549951,0661,0019729471,0049951,0169791,024
Consumables($M)
764775726756747740696698741729691682
Service($M)
155154151156147136142152150171178181
Instruments($M)
10212511815410796109154104116110161
Microarray($M)3
108105969383879410085969798
Consumables($M)
777771766971728166787174
Service($M)
282323131011191416142218
Instruments($M)
352445353446
GRAIL($M)
000000292731
Consumables($M)
841852797832816811768779807807762756
Service($M)
183177174169157147161166166185200199
Instruments($M)
105130120158111101112159107120114167
Americas($M)
638612586570589609640603601
United States and Canada($M)
637653590596569555
Europe($M)
353309310293326291289279315
Europe, Middle East, Africa and Latin America($M)
347368356354355332
Asia-Pacific, Middle East and Africa($M)
112111100106109105108116124
Asia-Pacific($M)
868293827282
China($M)
595652565263728075757882
Kỳ báo cáo trước đây (báo cáo lần cuối 2026)2
Kỳ báo cáo trước đây (báo cáo lần cuối 2026)1
Remaining performance obligations (RPO)($M)
9331,0001,100747862891688717796
Remaining Performance Obligations — Product & Instrument Service Backlog ($M)($M)3
9331,0001,100738747862891657688717796653
RPO Expected to Convert to Revenue Within 12 Months (%)(%)
76.0%83.0%85.0%77.0%77.0%79.0%83.0%78.0%82.0%82.0%87.0%82.0%
RPO Expected to Convert to Revenue in 13–24 Months (%)(%)
14.0%11.0%9.0%13.0%11.0%10.0%7.0%10.0%13.0%13.0%9.0%13.0%
Development and Licensing Remaining Performance Obligations ($M)($M)
334338
Total Contract Liabilities — Deferred Revenue ($M)($M)3
319333344346307324329327293305324329
Current Contract Liabilities — Short-Term Deferred Revenue ($M)($M)
250261269270234247256260235238248252
Revenue Recognized from Beginning Contract Liability Balance ($M)($M)
4771983047709748709539
Contract Assets, Net ($M)($M)
202023212215151616161518
High-Throughput Sequencing Volume Share on NovaSeq X Platform (%)(%)5
84.0%83.0%82.0%69.0%
High-Throughput Consumables Revenue Share on NovaSeq X Platform (%)(%)
60.0%59.0%55.0%55.0%44.0%
Research & Applied High-Throughput Volume Share on NovaSeq X (%)(%)
90.0%90.0%90.0%90.0%
Clinical High-Throughput Volume Share on NovaSeq X (%)(%)
78.0%78.0%76.0%55.0%
Clinical Sequencing Consumables Revenue Growth YoY, Rest of World Ex-China (%)(%)
14.0%15.0%20.0%20.0%
Research & Applied Sequencing Consumables Revenue Growth YoY, Rest of World Ex-China (%)(%)
-6.0%-7.0%-12.0%
Rest-of-World (Ex-Greater China) Organic Revenue Growth YoY (%)(%)5
4.7%8.1%3.5%
Consolidated Organic Revenue Growth YoY (%)(%)
4.8%6.5%1.2%
Reported Consolidated GAAP Revenue Growth YoY (%)(%)
4.2%9.5%4.8%
Revenue Growth Impact from Acquisitions YoY (%)(%)
-2.4%-2.1%-1.7%
Revenue Growth Impact from Foreign Currency Exchange Rates YoY (%)(%)
-0.4%-0.9%-1.9%
Revenue Growth Offset from Greater China Exclusion YoY (%)(%)
-0.1%1.6%2.3%
Total Disaggregated Revenue by Source ($M)($M)3
1,1291,1591,0911,1591,0841,0591,0411,1041,0801,1121,0761,122
Total Sequencing Revenue ($M)($M)1
1,0211,0549951,0661,0019729471,0049951,0169791,024
Sequencing Product Revenue ($M)($M)
866900844910854836805852845845801843
Total Microarray Revenue ($M)($M)1
108105969383879410085969798
Microarray Product Revenue ($M)($M)
808273807376758669827580
Total Consolidated Product Revenue ($M)($M)
946982917990927912880938914927876923
Unaudited Pro Forma Combined Revenue Including SomaLogic ($M)($M)1
1,1291,1591,0991,1081,0761,060
Unaudited Pro Forma Combined Net Income Including SomaLogic ($M)($M)
21819214114024176
Selling and Marketing Expense ($M)($M)
159164158160148146165158163165153
General and Administrative Expense ($M)($M)
1221091141491298810212176-105183
Total Share-Based Compensation Expense Before Taxes ($M)($M)8
7572606370697380841109694
Share-Based Compensation — Cost of Product Revenue ($M)($M)
454456567757
Share-Based Compensation — Cost of Service and Other Revenue ($M)($M)
101111111122
Share-Based Compensation — Research and Development ($M)($M)
252624232628303133433938
Share-Based Compensation — Selling, General and Administrative ($M)($M)
454131353834374243595047
Share-Based Compensation Related Income Tax Benefits ($M)($M)
171613151515161718262222
Share-Based Compensation Expense, Net of Taxes ($M)($M)
585647485554576366847472
Unrecognized Share-Based Compensation Cost ($M)($M)
442494576391462553687565655735834496
Weighted-Average Recognition Period for Unrecognized Share-Based Compensation (Years)(năm)
2.02.32.52.32.32.52.72.52.5
Total Current Inventories, Net ($M)($M)6
667629611564590575537547574561584587
Raw Materials Inventory ($M)($M)
319295268254251227216225238232262276
Work in Process (WIP) Inventory ($M)($M)
434426427398418419404404419416405402
Finished Goods Inventory ($M)($M)
585755455047263137353530
Total Gross Inventory Before Reserves ($M)($M)
811778750697719693646660694683702708
Inventory Valuation and Obsolescence Reserves ($M)($M)
119123119133129118109113120122118121
Non-Current Work in Process Inventory ($M)($M)
2526200
Reserve for Product Warranties — Ending Balance ($M)($M)2
141716171416171816172021
Product Warranty Reserve — Additions Charged to Cost of Product Revenue ($M)($M)
46611368128101212
Product Warranty Reserve — Repairs and Replacements Deductions ($M)($M)
7578579109131310
Total Government Assistance Grants Receivable ($M)($M)1
56452421
Current Government Assistance Grants Receivable ($M)($M)
151838
Common Shares Repurchased Under Authorized Programs (Thousand Shares)5
479422,0053371,2364,4891,728134770
Total Cost of Common Shares Repurchased ($M)($M)
9123243421213842011799
Weighted-Average Price Paid per Repurchased Share ($/Share)($)
19112912112497.1084.66116129128
Remaining Share Repurchase Authorization ($M)($M)
1,7701,7794006436848041,1841,3841,402
Cash Paid for Common Stock Repurchases ($M)($M)
9128242421303702001799000
Treasury Stock Carrying Value ($M)($M)
5,0655,0544,9314,6994,6454,5234,1393,9343,8933,7943,7933,792
Non-GAAP Gross Profit ($M)($M)5
8507907442,9647507357022,9732,2281,466708
Non-GAAP Gross Margin (%)(%)
75.3%68.2%68.2%68.2%69.2%69.4%67.4%68.6%69.0%68.3%67.1%
Non-GAAP Operating Profit ($M)($M)
325260239275265252212218244
Non-GAAP Operating Margin (%)(%)
28.8%22.5%21.9%23.7%24.5%23.8%20.4%19.7%22.6%
Non-GAAP Diluted Earnings per Share ($/Share)($)
1.621.311.151.351.341.190.970.951.141.090.98
Free Cash Flow — Form 8-K Reconciliation ($M)($M)
3781622512672532042083222844841173
GRAIL Total Revenue ($M)($M)6
37.544.740.836.235.531.8
GRAIL Galleri Multi-Cancer Early Detection Screening Revenue ($M)($M)2
37.342.639.832.834.429.1
Galleri Screening Test Sales Volume Growth YoY (%)(%)
24.0%35.0%50.0%
Galleri Screening Test Average Selling Price (ASP) Change YoY (%)(%)
-9.0%-8.0%-9.0%
GRAIL Development Services Revenue ($M)($M)
0.272.040.953.391.172.70
GRAIL Cost of Screening Revenue — Exclusive of Amortization ($M)($M)
22.023.421.215.919.417.1
GRAIL Research and Development Expense ($M)($M)
44.147.448.048.746.653.6
GRAIL Sales and Marketing Expense ($M)($M)
41.737.730.725.528.535.0
GRAIL General and Administrative Expense ($M)($M)
40.750.742.837.437.945.1
Illumina Premarket Approval (PMA) Original & Supplement Approvals (Approvals)2
220021011000
Illumina Medical Device Enforcement Recall Events (Events)
000100000000
Illumina MAUDE Medical Device Adverse Event Reports (Reports)
010010000100
U.S. Industry-Wide 510(k) Medical Device Clearances (Clearances)2
855923756806797886736856767793713877
U.S. Industry-Wide PMA Medical Device Approvals (Approvals)
565608567525585588524683538550459656
U.S. Industry-Wide MAUDE Medical Device Adverse Event Reports (Reports)
1,189,467923,529811,618751,012819,444632,296685,251709,498699,798631,546586,309573,619
U.S. PPI — Analytical Laboratory Instruments (WPU118501, Index 1985=100)(×)3
203.64203.64202.01197.85195.85195.49195.29191.73191.56191.72190.66186.75
U.S. PPI — In-Vitro Diagnostic Substance Manufacturing (PCU325413325413, Index)(×)
300.64302.78304.31300.43298.72297.45292.10284.59284.49284.62285.08283.01
U.S. PPI — Medical and Diagnostic Laboratories (PCU621511621511, Index)(×)
101.50101.52101.38101.29101.29101.26101.17100.87100.91100.97100.79100.86
U.S. PPI — Surgical and Medical Instrument Manufacturing (PCU339112339112, Index)(×)
163.38162.89161.74159.58157.80156.88157.06155.15154.40154.13153.62151.03
Consolidated Revenue ($M)($M)15
1,1291,1591,0911,1591,0841,0591,0411,1041,0801,1121,0761,122
Cost of Revenue ($M)($M)
299389370400351364358376335391409448
Gross Profit ($M)($M)
830770721759733695683728745721667674
Research and Development Expense ($M)($M)
244252240239229247252256253325339341
Selling, General and Administrative Expense ($M)($M)
281273272309277234267279239147439485
Total Operating Expenses ($M)($M)
52552551255850648151955342,358778838
Operating Income ($M)($M)
305245209201227214164175741-1,637-111-164
Interest Income ($M)($M)
1281110910111011131211
Interest Expense ($M)($M)
242424262525252536201818
Income Before Income Taxes ($M)($M)
264260157377220306182187720-1,976-109-167
Provision for Income Taxes ($M)($M)
4453234370715101512178
Consolidated Net Income ($M)($M)
220207134334150235131186705-1,988-126-176
Basic Earnings per Share ($/Share)($)
1.461.370.880.981.490.834.43-12.48-0.79
Diluted Earnings per Share ($/Share)($)
1.431.350.870.981.490.824.42-12.48-0.79
Weighted-Average Basic Shares Outstanding (Million Shares)(M)
151151153153157159159159159
Weighted-Average Diluted Shares Outstanding (Million Shares)(M)
154153154154157159160159159
Total Assets ($M)($M)12
6,8126,6506,5596,6446,1776,0876,1826,3036,0146,08110,04010,111
Cash and Cash Equivalents ($M)($M)
1,2891,0401,0891,4181,0509341,1131,1278699201,1081,048
Short-Term Investments ($M)($M)
48128662152282211249370746
Accounts Receivable, Net ($M)($M)
738764738854729701699735699641635734
Inventories, Net ($M)($M)
667629611564590575537547574561584587
Property, Plant and Equipment, Net ($M)($M)
7317457557597487647828158328599641,007
Operating Lease Right-of-Use Assets ($M)($M)
356362371370382397410419453460550544
Goodwill ($M)($M)
1,2841,2841,2841,1131,1131,1131,1131,1131,1131,0792,5452,545
Intangible Assets, Net ($M)($M)
3914104302102252382782953052782,9402,993
Accounts Payable ($M)($M)
241230218240218200207221191199201245
Accrued Liabilities ($M)($M)
9158488498467467627348277841,2651,2731,325
Long-Term Debt ($M)($M)
1,7891,4911,4901,4909941,4921,4911,4901,9881,4901,4901,489
Total Stockholders' Equity ($M)($M)
3,1452,8382,6762,7232,3812,2582,3682,3732,1251,4365,7345,745
Operating Cash Flow ($M)($M)2
4192012893212842342403643168077224
Capital Expenditures ($M)($M)
404038553130322932313651
Stock-Based Compensation — Cash Flow Statement ($M)($M)
7572606370697379841109694
Core Illumina Segment Revenue — Through Q2 2026 ($M)($M)1
1,1591,0911,1591,0841,0591,0411,1041,0801,0921,0561,097
Total Product Revenue — Product Series Through Q2 2026 ($M)($M)
982917990927912880938914927876923

15 chỉ số không có số liệu trong 12 quý gần nhất — .

In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).

Phương pháp và các chỉ số bị loại
  • Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
  • Remaining Performance Obligations (RPO / Backlog) in Group 1 represent the aggregate transaction price allocated to unsatisfied or partially unsatisfied performance obligations for product and instrument service contracts as disclosed in Note 2 of Form 10-K and Form 10-Q ($933.0 million as of Q3 2026, with 76% expected to convert to revenue within 12 months and 14% in months 13–24, plus $33.0 million of Development and Licensing RPO).
  • Period-splitting formulas: Quarterly flow series reported on a three-month (Q1–Q3), six-month (6M), and nine-month (9M) basis in Form 10-Q and on a full-year basis in Form 10-K (Note 2 Revenue by Source matrix, Greater China & legacy regional revenues, ASU 2023-07 Selling & Marketing and General & Administrative expenses, Share-Based Compensation by function, Product Warranty additions and repairs, and Cash Flow statement items) derive fourth-quarter values via Q4 = full year (10-K) − nine months (10-Q) from the same reporting basis.
  • Consolidated vs. parent-only financial statements: Illumina prepares consolidated financial statements in accordance with U.S. GAAP and does not file standalone parent-only financial statements (Schedule I is not required). Following the June 24, 2024 spin-off of GRAIL, Inc. (in which Illumina retains a 14.5% equity stake), GRAIL's standalone revenue, Galleri test volume/ASP growth rates, and operating expenses are presented in Group 5 from GRAIL's Form 10-Q filings.
  • Commercial region realignment in Q1 2026: Beginning in Q1 2026, Illumina reorganized its global commercial structure into four regions — United States and Canada (USCAN), Europe, Middle East, Africa and Latin America (EMEALA), Greater China, and Asia-Pacific (APAC) — with comparative 2025 periods restated. Legacy regional series (Americas, Europe, and APMEA) are preserved through their structural break at FY2025Q4.

Không hiện vì thiếu các kỳ gần đây (9)

  • High-Throughput Sequencing Volume Share on NovaSeq X Platform (%) › Exact Quarterly NovaSeq X Instrument Shipments (Units — Point Disclosures Only)
  • High-Throughput Sequencing Volume Share on NovaSeq X Platform (%) › Cumulative Active NovaSeq X Installed Base (Instruments — Point Disclosures Only)
  • High-Throughput Sequencing Volume Share on NovaSeq X Platform (%) › Share of Quarterly NovaSeq X Placements to Clinical Customers (%)
  • High-Throughput Sequencing Volume Share on NovaSeq X Platform (%) › Clinical End-Market Share of Total Sequencing Consumables Revenue (%)
  • Rest-of-World (Ex-Greater China) Organic Revenue Growth YoY (%) › Revenue Growth Impact from Customer IEEPA Tariff Refunds YoY (% — Q3 2026 Only)
  • Total Government Assistance Grants Receivable ($M) › Government Incentive Benefits Recognized in Operating Income ($M)
  • Global Workforce — Total Employees (Employees) › Issued U.S. Patents Owned or Exclusively Licensed (Patents — Discontinued After FY2022)
  • Global Workforce — Total Employees (Employees) › Pending U.S. Patent Applications (Applications — Discontinued After FY2022)
  • Global Workforce — Total Employees (Employees) › Women Share of Global Workforce — Form 10-K Item 1 (% — Discontinued After FY2023)

Dữ liệu cập nhật 2026-11-09.

Mỗi KPI một trang riêng

Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số

5. GRAIL, Inc. Standalone Disclosures (Former Consolidated Subsidiary; 14.5% Retained Stake)

Tài liệu nguồn mới nhất

Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Illumina

See a number that looks wrong?